Skip to content
Catalyst

PapersPMID:27208415

Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.

Aging2016The record ↗

findings
4
compound
1
endpoints
4
PMID:27208415
  1. Finding, moderate evidenceno difference foundC-reactive protein concentration
  2. Finding, moderate evidenceno difference foundFlow-mediated dilation
  3. Finding, moderate evidenceno difference foundInterleukin-6 concentration
  4. Finding, moderate evidenceno difference foundTumour necrosis factor alpha concentration
Study, every finding
RCT · 3 months
Dose studied, every finding
100 g/day trehalose dissolved in 12 ounces of water, 12 weeks

No finding here moved its endpoint.

  • “There were no baseline group differences in oxidized LDL, CRP, IL-6 or TNF-α and these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4).”
  • “FMD did not change differentially across the intervention in the trehalose and maltose treated groups when FMD was expressed as either percent or absolute change (both P>0.1, Figure 6).”
    Population
    Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers (trehalose 15, maltose 17); comparator maltose 100 g/day, an isocaloric disaccharide

Study record

Design
randomised controlled trial
Species
human
Population
healthy non-smoking middle-aged and older men and postmenopausal women aged 50-77 years
Participants
32
Comparator
an active treatment
Duration
84 days
Endpoints measured
45